Facebook Instagram X-twitter Linkedin

Tesamorelin (10mg)

Table of Contents

  • Quickstart Highlights

Tesamorelin (10mg) protocols focus on this synthetic growth hormone–releasing hormone (GHRH) analog, designed to stimulate the pituitary gland to increase natural growth hormone secretion. It is primarily studied for its role in reducing visceral fat and supporting improved body composition through elevated IGF-1 levels. This guide outlines a subcutaneous administration approach optimized for the 10 mg vial format.

  • Reconstitute: Add 2.0 mL bacteriostatic water → 5 mg/mL concentration
  • Typical daily range: 1–2 mg once daily (subcutaneous)
  • Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg (0.05 mg) on a U-100 insulin syringe
  • Storage: Lyophilized: store at −20 °C; after reconstitution, refrigerate at 2–8 °C and use within 2–4 weeks
  • Protocol Overview

Concise summary of the subcutaneous regimen.

  • Goal: Support reduction of visceral fat and enhance endogenous growth hormone secretion
  • Schedule: Daily subcutaneous injections, typically consistent timing each day
  • Dose Range: 1–2 mg per day (under clinical or supervised use)
  • Dosing Protocol

Suggested approach for the 10 mg vial format.

  • Start: 1 mg once daily to assess tolerance
  • Target: 2 mg once daily (standard studied dose range)
  • Frequency: Once daily (subcutaneous)
  • Vial Duration: One 10 mg vial lasts approximately 5–10 days, depending on dosing
  • Timing: Usually administered in the evening or before bed to align with the natural GH rhythm

Note: Use should be based on clinical guidance where applicable.

  • Mechanism of Action

Tesamorelin is a synthetic analog of growth hormone–releasing hormone (GHRH). It binds to GHRH receptors in the pituitary gland, stimulating the natural pulsatile release of growth hormone (GH). This leads to increased circulating insulin-like growth factor 1 (IGF-1), which mediates many of its downstream metabolic effects.

Through GH/IGF-1 signaling pathways, Tesamorelin may promote lipolysis, particularly in visceral adipose tissue, while supporting lean tissue maintenance. It has been studied most notably in individuals with HIV-associated lipodystrophy, where it demonstrated reductions in abdominal fat accumulation.

  • Potential Benefits & Side Effects

Observations based on clinical research and approved medical use.

Potential Benefits:

  • May reduce visceral (abdominal) fat accumulation
  • May improve body composition via GH/IGF-1 pathway activation
  • May support metabolic function and lipid profiles
  • May enhance overall tissue regeneration and metabolic health markers

Possible Side Effects:

  • Injection-site reactions (redness, swelling, irritation)
  • Mild joint pain or muscle stiffness
  • Increased IGF-1 levels (requires monitoring in clinical settings)
  • Headache or nausea in some users
  • Not intended for unsupervised use; prescription and monitoring required in approved indications